$150,000 of PHIBRO ANIMAL HEALTH CORPORATION lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Agency focused engagement. Issues regarding regulatory methods of testing veterinary drugs. Agency focused engagement. Issues regarding regulatory methods of testing veterinary drugs."
You can find more data on corporate lobbying on Quiver Quantitative.
PAHC Insider Trading Activity
PAHC insiders have traded $PAHC stock on the open market 91 times in the past 6 months. Of those trades, 0 have been purchases and 91 have been sales.
Here’s a breakdown of recent trading of $PAHC stock by insiders over the last 6 months:
- JACK BENDHEIM (President and CEO) has made 0 purchases and 91 sales selling 542,554 shares for an estimated $25,515,662.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PAHC Hedge Fund Activity
We have seen 104 institutional investors add shares of PAHC stock to their portfolio, and 112 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 626,492 shares (+4227.1%) to their portfolio in Q4 2025, for an estimated $23,405,741
- OBERWEIS ASSET MANAGEMENT INC/ added 209,800 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,838,128
- CASTLEKNIGHT MANAGEMENT LP removed 158,886 shares (-39.7%) from their portfolio in Q4 2025, for an estimated $5,935,980
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 151,711 shares (-74.5%) from their portfolio in Q4 2025, for an estimated $5,667,922
- ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC removed 102,350 shares (-46.8%) from their portfolio in Q4 2025, for an estimated $3,823,796
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 99,876 shares (-33.1%) from their portfolio in Q4 2025, for an estimated $3,731,367
- ADVISORS PREFERRED, LLC removed 96,886 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,619,660
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PAHC Analyst Ratings
Wall Street analysts have issued reports on $PAHC in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 11/07/2025
To track analyst ratings and price targets for PAHC, check out Quiver Quantitative's $PAHC forecast page.
PAHC Price Targets
Multiple analysts have issued price targets for $PAHC recently. We have seen 2 analysts offer price targets for $PAHC in the last 6 months, with a median target of $56.0.
Here are some recent targets:
- Daniel Grosslight from Citigroup set a target price of $62.0 on 04/15/2026
- Ekaterina Knyazkova from JP Morgan set a target price of $50.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
